Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression.
Frederick Berro RiveraSung Whoy ChaJohn Vincent MagalongNathan Ross B BantayanLinnaeus Louisse A CruzEloise Arias-AguirreZedrick AguirreMichelle Capahi VaronaElaiza Marie Fernandez CoGrace Nooriza Opay LumbangByambaa EnkhmaaPublished in: Current medical research and opinion (2024)
Alirocumab decreased adverse events leading to death. Alirocumab and Evolocumab both decreased serious adverse events. PCSK9i did not increase new onset DM however evolocumab worsened DM in the first 24 weeks of treatment. PCSK9i did not increase neurologic dysfunction, and did not elevate liver enzymes and CK, however it was associated with local injection site reaction.